Cancer
Malignant Gastric Neoplasm
CI-CAN-00001130Explore in graph →
Top-level650 active trials4 approved drugs55 evidence items
Loading cancer entity…
Cancer
CI-CAN-00001130Explore in graph →
Clinical trials
2,844 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (232)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03823144 | Intravital Microscopy in Human Solid Tumors | recruiting | N/A | 85 | Mayo ClinicOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer |
| recruiting |
| N/A |
| 53 |
| Samsung Medical CenterOTHER |
| 1 |
| May 28, 2026 |
| clinicaltrials |
| NCT06937567 | CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05977998 | A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07593820 | A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.(Catherine) | recruiting | Phase 1 | 15 | Vall d'Hebron Institute of OncologyOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07481357 | A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 | 51 | Dong-A ST Co., Ltd.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT06503146 | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | recruiting | Phase 2 | 320 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT07594964 | To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors | recruiting | Phase 1 | 48 | Shenzhen Xinhe BiomedicalINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT01514045 | The Gastric Cancer Foundation: A Gastric Cancer Registry | recruiting | — | 500 | Stanford UniversityOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04421820 | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 220 | Bold Therapeutics, Inc.INDUSTRY | 7 | May 18, 2026 | clinicaltrials |
| NCT05698992 | Rehabilitation and Recovery for Persons With Esophageal or Gastric Cancer | recruiting | — | 100 | Region SkaneOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06580574 | Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers | recruiting | Phase 2 | 34 | Peking UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07401199 | Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC) | recruiting | — | 2,000 | Qun ZhaoOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05702229 | Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 163 | AstraZenecaINDUSTRY | 7 | May 14, 2026 | clinicaltrials |
| NCT07432295 | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | recruiting | Phase 2 | 180 | I-Mab Biopharma US LimitedINDUSTRY | 3 | May 14, 2026 | clinicaltrials |
| NCT07587229 | Alternative Splicing Based Prediction of Chemotherapy Response in Gastric Cancer | recruiting | — | 329 | City of Hope Medical CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07307560 | High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients | recruiting | N/A | 600 | Zhejiang UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02838836 | Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers | recruiting | — | 620 | University of Missouri-ColumbiaOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07007182 | Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer | recruiting | Phase 2 | 54 | Jinbo YueOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07178808 | PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER | recruiting | Phase 2 | 30 | Banner HealthOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07542652 | Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis | recruiting | — | 450 | Yongquan ShiOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06385691 | Study Evaluating the Efficacy of the myDIET Software Tool in the Nutritional Management of Patients With Localized and Resectable Gastric or Esogastric Junction Cancer.(MyDIET) | recruiting | Phase 2 | 60 | Centre Leon BerardOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06846346 | Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma(GRACIE) | recruiting | Phase 2 | 88 | UNICANCEROTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05187182 | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer | recruiting | Phase 1 | 42 | Washington University School of MedicineOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06597227 | Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy(TJHGC01) | recruiting | N/A | 404 | Guihua WangOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07551362 | Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer(DUET-GEJ) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07551466 | AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging(XAI-EGC) | recruiting | — | 100 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07353684 | Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer | recruiting | Phase 2 | 49 | Beijing Friendship HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07441785 | Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer(PROXISTAT) | recruiting | — | 400 | P. Herzen Moscow Oncology Research InstituteOTHER_GOV | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06893133 | ctDNA-MRD Monitoring After Resection in Gastric Cancer(MRD-GC) | recruiting | — | 110 | Peking UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07537348 | Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer(LUCENT-GC-03) | recruiting | Phase 2 | 73 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537361 | Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer(LUCENT-GC-02) | recruiting | Phase 2 | 108 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03259867 | Combination of TATE and PD-1 Inhibitor in Liver Cancer(TATE-PD1) | recruiting | Phase 2 | 54 | Teclison Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04943484 | ICG (Indocyanine Green) Imaging Fluorescence Technology in Surgical Treatment of Advanced Gastric Cancer(iGreenGO) | recruiting | — | 360 | Niguarda HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03161522 | Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07525765 | AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer | recruiting | — | 7,000 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05927857 | Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . | recruiting | Phase 1 / Phase 2 | 45 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07401173 | DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective) | recruiting | — | 500 | Qun ZhaoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05753306 | Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07517107 | Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer | recruiting | Phase 2 | 600 | Fudan UniversityOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07517432 | The UGIRA International Registry for RAMIG for Gastric Cancer | recruiting | — | 200 | Chinese University of Hong KongOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05226169 | Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC) | recruiting | Phase 3 | 330 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05514769 | Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer | recruiting | N/A | 60 | Nanchong Central HospitalOTHER_GOV | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06464978 | Stapler Reinforcement Patches Compared to Standard Staplers in Gastrojejunostomy | recruiting | N/A | 382 | Nanchong Central HospitalOTHER_GOV | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07504367 | Large Language Models Assist in Tumor MDT | recruiting | N/A | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 31, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 2, 2026source: clinicaltrials